Advanced search×

AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development.

Samir N SN Khleif, James H JH Doroshow, William N WN Hait, and

Clin Cancer Res 16(13):3299-318 (2010) PMID 20501613

Recent discoveries in cancer biology have greatly increased our understanding of cancer at the molecular and cellular level, but translating this knowledge into safe and effective therapies for cancer patients has proved to be challenging. There is a growing imperative to modernize the drug development process by incorporating new techniques that can predict the safety and effectiveness of new drugs faster, with more certainty, and at lower cost. Biomarkers are central to accelerating the identification and adoption of new therapies, but currently, many barriers impede their use in drug development and clinical practice. In 2007, the AACR-FDA-NCI Cancer Biomarkers Collaborative stepped into the national effort to bring together disparate stakeholders to clearly delineate these barriers, to develop recommendations for integrating biomarkers into the cancer drug development enterprise, and to set in motion the necessary action plans and collaborations to see the promise of biomarkers come to fruition, efficiently delivering quality cancer care to patients.

DOI: 10.1158/1078-0432.CCR-10-0880
Version: za2963e q8za0 q8zbb q8zca q8zdc q8ze0 q8zf0 q8zga

Similar articles you may find interesting…

  1. ADAM-17: a target to increase chemotherapeutic efficacy in colorectal cancer?
    Adam M AM Lee and Robert B RB Diasio

    Clin Cancer Res 16(13):3319-21 (2010) PMID 20570925

    Chemotherapy-induced activation of ADAM-17 results in increased growth factor shedding and activation of growth factor receptor-mediated pro-survival response. Enhanced ADAM-17 activity and HER ligand shedding results in resistance to chemotherapy in CRC. Therapies that decrease ADAM...
  2. New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK.
    Giorgia G Zadra, Carmen C Priolo, ... Massimo M Loda

    Clin Cancer Res 16(13):3322-8 (2010) PMID 20423984

    We review evidence that the metabolic sensor 5'-AMP-activated protein kinase (AMPK), which physiologically integrates nutritional and hormonal signals and regulates cell survival and growth-related metabolic pathways to preserve intracellular ATP levels, represents a link between energy homeostasis...
  3. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response.
    Christine A CA Pratilas and David B DB Solit

    Clin Cancer Res 16(13):3329-34 (2010) PMID 20472680

    Mitogen-activated protein kinase (MAPK) pathway activation is a frequent event in human cancer and is often the result of activating mutations in the BRAF and RAS oncogenes. Targeted inhibitors of BRAF and its downstream effectors are in various stages of preclinical and clinical dev...